1st Faculty of Medicine Charles University 1st Faculty of Medicine Charles University Stopka Lab
tstopka 25.03.2020

2005 - now

2020

  • Loss of ISWI ATPase SMARCA5 (SNF2H) in Acute Myeloid Leukemia Cells Inhibits Proliferation and Chromatid Cohesion. Zikmund T, Paszekova H, Kokavec J, Kerbs P, Thakur S, Turkova T, Tauchmanova P, Greif PA, Stopka T. Int J Mol Sci. 2020;21(6):E2073. Published 2020 Mar 18. doi:10.3390/ijms21062073. (IF 4.183) [PubMed]

  • The chromatin remodeler Snf2h is essential for oocyte meiotic cell cycle progression. Zhang C, Chen Z, Yin Q, Fu X, Li Y, Stopka T, Skoultchi AI, Zhang Y.  Genes Dev. 2020 Jan 9. doi: 10.1101/gad.331157.119. (IF 8.998) [PubMed]

2019

  • ISWI ATPase Smarca5 Regulates Differentiation of Thymocytes Undergoing b-selection.Zikmund T, Kokavec J, Turkova T, Savvulidi P, Paszekova H, Vodenkova S, Sedlacek R, Skoultchi AI, and Stopka T. Journal of Immunology. J Immunol. 2019 Jun 15;202(12):3434-3446. doi: 10.4049/jimmunol.1801684. (IF 4.539) [PubMed]
     
  • Paraproteinemic keratopathy associated with monoclonal gammopathy of undetermined significance (MGUS): clinical findings in twelve patients including recurrence after keratoplasty. Skalicka P, Dudakova L, Palos M, Huna L, Evans CJ, Mahelkova G, Meliska M, Stopka T, Tuft S, Liskova P. Acta Ophthalmologica. Acta Ophthalmol. 2019 May 2. doi: 10.1111/aos.14123. (IF 3.032) [PubMed]
     
  • Azacitidine Switch to Lenalidomide Eradicated the TP53/ CDKN2A Co-Mutated Clone and Induced Long-Term Erythroid Response in Del(5q) MDS. Minarik L, Zemanova Z, Kulvait V, Dluhosova M, Jonasova A and Stopka T. Ann Hematol Oncol. 2019; 6(1): 0000. (IF 2.219) [PDF]  
  •  
  • Randomizovaná otevřená akademická studie: srovnání standardního podání azacytidinu oproti azacytidinu s preinkubací G-CSF u myelodysplastického syndromu vyššího rizika – interim analýza. Stopka T, Minařík Ĺ, Kulvait V, Pešta M, Schaffartziková A, Kislik G, Dusílková N, Zemanová Z, Jonášová A. Myelodysplastic Syndrome News. Listopad 2019. Ročník 7 / číslo 2. [PDF]

2018

  • BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.Srutova K, Curik N, Burda P, Savvulidi F, Silvestri G, Trotta R, Klamova H, Pecherkova P, Sovova Z, Koblihova J, Stopka T, Perrotti D, Machova Polakova K. Haematologica. 2018 Jul 26. pii: haematol.2018.193086. doi: 10.3324/haematol.2018.193086. (IF 9.9) [PubMed] (I, 131)
     
  • Lenalidomide treatment in lower risk myelodysplastic syndromes—The experience of a Czech hematology center. (Positive effect of erythropoietin±prednisone addition to lenalidomide in refractory or relapsed patients). Jonasova A, Neuwirtova R, Polackova H, Siskova M, Stopka T, Cmunt E, Belickova M, Moudra A, Minarik L, Fuchs O, Michalova K, Zemanova Z. Leukemia Research 69 (2018) 12-17. 2018 March 27. https://doi.org/10.1016/j.leukres.2018.03.015 . (IF 2.501) [PDF] (H, 131)
     
  • 1. interim analýza randomizované otevřené klinické studie GA-MDS/2013. Dusilkova N, Minarik L, Stopka T, Jonasova A. Myelodysplastic Syndrome NEWS. Ročník 6 / Číslo 1 / květen 2018. [PDF] (N, 131)

2017

  • Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selectin in patients-responders. Polgarova K, Vargova K, Kulvait V, Dusilkova N, Minarik L, Zemanova Z, Pesta M, Jonasova A and Stopka T. Oncotarget. 2017 Dec 6. (IF 5.168) [PDF] (B, N, H, 131)
     
  • Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-cell Lymphomas. Dusilkova N, Basova P, Polivka J, Kodet O, Kulvait V, Pesta M, Trneny M, Stopka T. Int J Mol Sci. 2017 Oct 15;18(10). pii: E2136. doi: 10.3390/ijms18102136. (IF: 3.226) [PDF]
     
  • Prediction Potential of Serum miR-155 and miR-24 for Relapsing Early Breast Cancer. Basova P, Pesta M, Sochor M, Stopka T. Int J Mol Sci. 2017 Oct 10;18(10). pii: E2116. doi: 10.3390/ijms18102116(IF: 3.226) [PDF]
     
  • Kokavec J, Zikmund T, Savvulidi F, Kulvait V, Edelmann W, Skoultchi AI, Stopka T. The ISWI ATPase Smarca5 (Snf2h) Is Required for Proliferation and Differentiation of Hematopoietic Stem and Progenitor Cells. Stem Cells. 2017 Jun;35(6):1614-1623. doi: 10.1002/stem.2604. (IF: 5.599) [PubMed]
     
  • Huskova H, Ardin M, Weninger A, Vargova K, Barrin S, Villar S, Olivier M, Stopka T, Herceg Z, Hollstein M, Zavadil J, Korenjak M. Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing. Oncogene. 2017 Jul 10. doi: 10.1038/onc.2017.215. (IF: 7.519)[PDF]
     
  • Využití detekce somatických mutací pro pacienty s cytopenií nejasného významu a u myelodysplastického syndromu. Stopka T. Myelodysplastic Syndrome NEWS. Ročník 5 / Číslo 1 / květen 2017. [PDF]
     
  • Vargova K, Pesta M, Obrtlíkova P, Dusilkova N, Minarik L, Vargova J, Berkova A, Zemanova Z, Michalova K, Spacek M, Trneny M and Stopka T. MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia. Blood Cancer J. 2017 Jul 21;7(7):e585. doi: 10.1038/bcj.2017.63. (IF: 6.126) [PDF]

2016

  • DN Papageorgiou, E Karkoulia, A Amaral-Psarris, P Burda, K Kolodziej, JA Demmers, J Bungert, T Stopka, J Strouboulis. Distinct and overlapping DNMT1 interactions with multiple transcription factors in erythroid cells: evidence for co-repressor functions. Biochim Biophys Acta. 2016 Dec;1859(12):1515-1526. doi: 10.1016/j.bbagrm.2016.09.007. (IF: 5.373) [PubMed]
     
  • J. Vargova, K. Vargova, N.Dusilkova, V. Kulvait, V. Pospisil, J. Zavadil, M. Trneny, P. Klener, and T. Stopka. Differential Expression, Localization and Activity of MARCKS between Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia. Blood Cancer J. 2016 Sep 23;6(9):e475. (IF: 6.126) [PDF]
     
  • He S, Limi S, McGreal RS, Xie Q, Brennan LA, Kantorow WL, Kokavec J, Majumdar R, Hou H Jr, Edelmann W, Liu W, Ashery-Padan R, Zavadil J, Kantorow M, Skoultchi AI, Stopka T, Cvekl A. Chromatin remodeling enzyme Snf2h regulates embryonic lens differentiation and denucleation. Development. 2016 Jun 1;143(11):1937-47. doi: 10.1242/dev.135285. (IF 6.462) [PDF]
     
  • P Burda, J. Vargova, N Curik, C Salek, G Papadopoulos, J Strouboulis and T. Stopka. GATA-1 inhibits PU.1 gene via DNA and histone H3K9 Methylation of its Distal Enhancer in Erythroleukemia. PLoS One, 2016 Mar 24;11(3):e0152234 (IF 3.234)[PDF]

2015

  • H. Huskova, K. Korecka, J. Karban, K. Vargova, J. Vargova, N. Dusilkova, M. Trneny, and T. Stopka. Oncogenic microRNA-155 and its target PU.1: An integrative gene expression study in six of the most prevalent lymphomas. International Journal of Hematology, Int J Hematol. 2015 Oct;102(4):441-50. (IF 1.918) [PubMed]
     
  • K. Machova Polakova, V. Kulvait, Adela Benesova,J. Linhartova, H. Klamova, M. Jaruskova, C. de Benedittis, T. Haferlach, M. Baccarani, G. Martinelli, T. Stopka, T. Ernst, A. Hochhaus, A. Kohlmann, and S. Soverini. Next generation deep-sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol.2015 May;141(5):887-99. (IF 3.141)[PubMed]

2014

  • A. Laslo P* and Stopka T*.Transcriptional and epigenetic regulation in the development of myeloid cells: normal and diseased myelopoiesis. Book Chapter, 2014. “Epigenetics and Human Health” publisher: Springer*Equal Corresponding Author, in press 2013,  issued Feb2014
     
  • Dluhosova M, Curik N, Vargova J, Jonasova A, Zikmund T,Stopka T.Epigenetic control of SPI1 gene by CTCF and ISWI ATPase SMARCA5. PLoS One. 2014 Feb 3;9(2):e87448. (IF 3.534) [PDF]
     
  • Alvarez-Saavedra M, De Repentigny Y, Lagali PS, Raghu Ram EV, Yan K, Hashem E, Ivanochko D, Huh MS, Yang D, Mears AJ, Todd MA, Corcoran CP, Bassett EA, Tokarew NJ, Kokavec J, Majumder R, Ioshikhes I, Wallace VA, Kothary R, Meshorer E, Stopka T, Skoultchi AI, Picketts DJ. Snf2h-mediated chromatin organization and histone H1 dynamics govern cerebellar morphogenesis and neural maturation. Nat Commun. 2014 Jun 20;5:4181 (IF 11.470) [PDF]
     
  • Sochor M, Basova P, Pesta M, Dusilkova N, Bartos J, Burda P, Pospisil V, Stopka T. Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer. 2014 Jun 18;14:448.(IF 3.362) [PDF]
     
  • Basova P, Pospisil V, Savvulidi F, Burda P, Vargova K, Stanek L, Dluhosova M, Kuzmova E, Jonasova A, Steidl U, Laslo P, Stopka T. Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice. Oncogene. 2014 Sep 25;33(39):4735-45. doi: 10.1038/onc.2013.414. (IF 8.459) [PubMed]

2013

  • Machova Polakova K, Koblihova J, Stopka T. Role of epigenetics in chronic myeloid leukemia. Curr Hematol Malig Rep. 2013 Mar;8(1):28-36. doi: 10.1007/s11899-012-0152-z. (IF 2.3) [PDF]
     
  • N Curik, P Burda, K Vargova, V Pospisil, M Belickova, P Vlckova, F Savvulidi, E Necas, H Hajkova, C Haskovec, J Cermak, M Krivjanska, M Trneny, P Laslo, A Jonasova and T Stopka. 5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity. Leukemia, 2012 Aug;26(8):1804-11.(IF 9.51) [PubMed]
     
  • Vargova K, Curik N, Burda P, Basova P, Kulvait V, Pospisil V, Savvulidi F, Kokavec J, Necas E, Berkova A, Obrtlikova P, Karban J, Mraz M, Pospisilova S, Mayer J, Trneny M, Zavadil J, Stopka T. MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood. 2011 Apr 7;117(14):3816-25. (IF 10.5) [PubMed]
     
  • Pospisil V, Vargova K, Kokavec J, Rybarova J, Savvulidi F, Jonasova A, Necas E, Zavadil J, Laslo P, andStopka T. Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage differentiation. EMBO J. 2011 Sep 6. (IF 10.1) [PubMed]
     
  • Machová Poláková K, Lopotová T, Klamová H, Burda P, Trněný M, Stopka T, Moravcová J. Expression patterns of microRNAs associated with CML phases and their disease related targets. Mol Cancer. 2011 Apr 18;10:41. doi: 10.1186/1476-4598-10-41. (IF 3.78) [PubMed]

2010

  • Burda P., Laslo P. and Stopka T. The role of PU.1 and GATA-1 transcription factors during normal and leukemogenic hematopoiesis. Leukemia 2010, 1-9.(IF 8.3) [PubMed]
     
  • Michael Papetti, Sandeep N. Wontakal, Tomas Stopka and Arthur I. Skoultchi. GATA-1 directly regulates p21 gene expression during erythroid differentiation. Cell Cycle 9:10, 1-9; May 15, 2010.(IF 4.1) [PubMed]

2009

  • Vargova J, Vargova K, and Stopka T. Nuclear Localization of Chromatin Remodeling ISWI ATPase Smarca5 (Snf2h) in Mouse. Front Biosci. E1, 553-559, June 1, 2009 (IF 3.308) [PubMed]
     
  • Burda P, Curik N, Kokavec J, Basova P, Mikulenkova D, Skoultchi AI, Zavadil J and Stopka T. PU.1 Activation Relieves GATA-1–Mediated Repression of Cebpa and Cbfb during Leukemia Differentiation. Mol Cancer Res 2009, 7(10): OF1-11.(IF 4.533) [PubMed]
     
  • Kokavec J, Vargova J, Burda P, Vargova K, Necas E, Zavadil J, and Stopka T. SWI/SNF2 proteins in germinal and early embryonic development. Folia Zool. – 58 (Suppl. 1): (2009). (IF 0.522)

2008

  • Kokavec J, Podskocova J, Zavadil J, Stopka T. Chromatin remodeling and SWI/SNF2 factors in human disease. Front Biosci. 2008 May 1;13:6126-34 (IF 2.989) [PubMed]